NCT05300958

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer: A Single-armed, Phase II Trial

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The objective of the study is to evaluate the efficacy and safety of chemotherapy plus deferoxamine in metastatic breast cancer whose evaluation is stable disease with a trend of progression.

Detailed description

This is a phase II, single center, prospective, single arm clinical trial. A lot of in vitro and in vivo study demonstrate that deferoxamine can increase anti-tumor effect. The objective of the study is to evaluate the efficacy and safety of chemotherapy plus deferoxamine in metastatic breast cancer whose evaluation is stable disease with a trend of progression after second-line. This study plans to recruit 30 subjects.

Conditions

• Triple Negative Breast Cancer

Interventions

Type	Name	Description
DRUG	Deferoxamine Plus Chemotherapy	Deferoxamine：50mg/kg+500ml normal saline (NS)

Timeline

• Start date: 2022-03-21
• Primary completion: 2025-07-21
• Completion: 2025-07-21
• First posted: 2022-03-29
• Last updated: 2025-07-22

Locations

1 site across 1 country: China